Targetable kinase gene fusions in high-risk B-ALL: a study from the Children’s Oncology Group
Top Cited Papers
Open Access
- 22 June 2017
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 129 (25), 3352-3361
- https://doi.org/10.1182/blood-2016-12-758979
Abstract
Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a high-risk subtype characterized by genomic alterations that activate cytokine receptor and kinase signaling. We examined the frequency and spectrum of targetable genetic lesions in a retrospective cohort of 1389 consecutively diagnosed patients with childhood B-lineage ALL with high-risk clinical features and/or elevated minimal residual disease at the end of remission induction therapy. The Ph-like gene expression profile was identified in 341 of 1389 patients, 57 of whom were excluded from additional analyses because of the presence of BCR-ABL1 (n = 46) or ETV6-RUNX1 (n = 11). Among the remaining 284 patients (20.4%), overexpression and rearrangement of CRLF2 (IGH-CRLF2 or P2RY8-CRLF2) were identified in 124 (43.7%), with concomitant genomic alterations activating the JAK-STAT pathway (JAK1, JAK2, IL7R) identified in 63 patients (50.8% of those with CRLF2 rearrangement). Among the remaining patients, using reverse transcriptase polymerase chain reaction or transcriptome sequencing, we identified targetable ABL-class fusions (ABL1, ABL2, CSF1R, and PDGFRB) in 14.1%, EPOR rearrangements or JAK2 fusions in 8.8%, alterations activating other JAK-STAT signaling genes (IL7R, SH2B3, JAK1) in 6.3% or other kinases (FLT3, NTRK3, LYN) in 4.6%, and mutations involving the Ras pathway (KRAS, NRAS, NF1, PTPN11) in 6% of those with Ph-like ALL. We identified 8 new rearrangement partners for 4 kinase genes previously reported to be rearranged in Ph-like ALL. The current findings provide support for the precision-medicine testing and treatment approach for Ph-like ALL implemented in Children’s Oncology Group ALL trials.Keywords
This publication has 53 references indexed in Scilit:
- Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemiaBlood, 2017
- Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemiaNature Communications, 2016
- Deregulation of DUX4 and ERG in acute lymphoblastic leukemiaNature Genetics, 2016
- EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implicationsBlood, 2016
- Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic LeukemiaCancer Cell, 2016
- Identification of novel kinase fusion transcripts in paediatric B cell precursor acute lymphoblastic leukaemia withIKZF1deletionBritish Journal of Haematology, 2015
- Childhood Acute Lymphoblastic Leukemia: Progress Through CollaborationJournal of Clinical Oncology, 2015
- Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232Blood, 2015
- Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic LeukemiaCancer Cell, 2015
- BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signaturesHaematologica, 2015